Save 85% with brand Stivarga by Bayer - called Nublexa from Europe (English language package - available immediately) and 94% with the generic.
Click here for information on Natco generics (Immediate availability)
According to the European Medicines Agency, brand name Stivarga (Nublexa) originating from Europe is manufactured at the following site(s):Bayer AG
Kaiser-Wilhelm-Allee
51368 Leverkusen
Germany
Information about Stivarga (Regorafenib)
Stivarga (Regorafenib) is an oral targeted therapy medication used in the treatment of various types of cancer. It is classified as a multi-kinase inhibitor that works by interfering with cancer cell growth through the inhibition of specific enzymes involved in tumor cell proliferation, angiogenesis (formation of new blood vessels), and metastasis. Stivarga is typically used in patients with advanced or metastatic cancers that have not responded to other treatments.
Product Highlights
- For patients who have previously been treated with standard chemotherapy and other targeted therapies.
- For patients with metastatic or unresectable GISTs who have not responded to treatment with imatinib and sunitinib.
- For patients with advanced HCC who have been previously treated with sorafenib.
Key Ingredient
Key Benefits
- Regorafenib targets several pathways involved in cancer growth, making it effective in a variety of cancer types.
- Clinical trials have shown that Stivarga can extend progression-free survival in patients with colorectal cancer, GISTs, and HCC.
- It provides an option for patients whose cancers have not responded to other therapies.
- Stivarga is taken as a daily oral pill, providing convenience compared to intravenous cancer treatments.
Direction of Use
- Stivarga should be taken orally with food, typically once a day.
- The recommended dose is 160 mg daily for the first 4 weeks of a 6-week cycle (4 weeks of treatment, followed by 2 weeks off).
- It is important to follow the prescribed dosing schedule to maximize the benefits of the medication.
- If a dose is missed, patients should not double up on doses. They should take the next dose at the regular time instead.
Safety Concerns
- Regorafenib can cause liver damage, including elevated liver enzymes and liver failure. Liver function should be monitored regularly.
- It may cause high blood pressure, and blood pressure should be monitored during treatment. Hypertension can be managed with antihypertensive medications.
- Stivarga can increase the risk of bleeding, particularly in patients with recent surgery, active bleeding, or other conditions that predispose to bleeding.
- Side effects may include diarrhea, nausea, and vomiting. Serious gastrointestinal perforations or fistulas can also occur.
- Patients may experience fatigue, weakness, and a general feeling of being unwell, which can impact daily activities.
- A common side effect of regorafenib, causing redness, swelling, and pain on the palms of the hands or soles of the feet.
Avoid Stivarga (Regorafenib) If
- Patients with severe liver problems should avoid Stivarga, as it may exacerbate liver toxicity.
- Stivarga should not be used in patients with active bleeding or bleeding disorders, as it increases the risk of severe bleeding.
- Due to the increased bleeding risk, Stivarga should be avoided shortly after surgery or injury.
- Stivarga is not recommended during pregnancy due to potential harm to the fetus, and it is also not advised while breastfeeding as it can pass into breast milk.
- Individuals with uncontrolled hypertension or significant cardiovascular disease should use Stivarga cautiously and under strict medical supervision due to the risk of heart-related side effects.
